GTCR to sell Cord Blood Registry for $700 mln

AMAG Pharmaceuticals Inc. has agreed to buy Cord Blood Registry for $700 million. The deal is expected to close in third quarter. San Bruno, California-based Cord Blood, a newborn stem cell company, is a portfolio company of GTCR.

DealsNorth AmericaUSBriefs